Immunovia ABOSTO:IMMNOV +0.53%43 Median PS Value is kr11.65 as of Jun. 29, 2026, which is 100% below its 10-year median of 0.01. GuruFocus rates OSTO:IMMNOV with a GF Score™ of 43/100 and a GF Value™ of kr0.07 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 86 Medical Diagnostics & Research companies, Immunovia AB ranks better than 98.84% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Immunovia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.002. Immunovia AB's 10-Year median PS Ratio is 5825. Therefore, the Median PS Value for today is kr11.65.
As of today (2026-06-29), Immunovia AB's share price is kr0.19. Immunovia AB's Median PS Value is kr11.65. Therefore, Immunovia AB's Price to Median PS Value for today is 0.02.
The historical rank and industry rank for Immunovia AB's Median PS Value or its related term are showing as below:
OSTO:IMMNOV'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.01 Med: 0.01 Max: 0.02
Current: 0.02
During the past 13 years, the highest Price to Median PS Value of Immunovia AB was 0.02. The lowest was 0.01. And the median was 0.01.
OSTO:IMMNOV's Price-to-Median-PS-Value is ranked better than 98.84% of 86
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.88
vs OSTO:IMMNOV: 0.02
Immunovia AB (OSTO:IMMNOV) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Immunovia AB's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
0.19
/
11.65
=
0.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB Median PS Value Related Terms
Immunovia AB Median PS Value Historical Data
* Premium members only.
The historical data trend for Immunovia AB's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:IMMNOV vs TMO, DHR, IDXX: Median PS Value Comparison
For the Diagnostics & Research subindustry, Immunovia AB's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunovia AB Price-to-Median-PS-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Immunovia AB's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Immunovia AB's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 5825.
Immunovia AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunovia AB (OSTO:IMMNOV) has a Median PS Value of kr11.65 as of Jun. 29, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Immunovia AB and its competitors. This is 116400% above median its historical median of 0.01. Over the past decade, Immunovia AB's Median PS Value has ranged from 0.01 to 0.02. According to the industry distribution chart, Immunovia AB ranks #1 out of 86 companies in the Medical Diagnostics & Research industry, placing it in the top 1.2%.
Is Immunovia AB's Median PS Value too high?
Immunovia AB's current Median PS Value of kr11.65 is 116400% above median its 10-year median of 0.01. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.02. Based on the distribution chart, Immunovia AB ranks #1 out of 86 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Immunovia AB has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immunovia AB's Median PS Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Immunovia AB ranks #1 out of 86 companies for Median PS Value. This places Immunovia AB in the top 1% of its industry — outperforming the majority of peers. The industry median Median PS Value is 0.88. Historically, Immunovia AB's own Median PS Value has ranged from 0.01 to 0.02 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Medical Diagnostics & Research company?
The median Median PS Value among Medical Diagnostics & Research companies is 0.88, based on 86 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Immunovia AB and its competitors. For the Medical Diagnostics & Research industry, the median Median PS Value is 0.88 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunovia AB's current Median PS Value is kr11.65, which is 116400% above median its own 10-year median of 0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunovia AB stock overvalued right now?
Based on GuruFocus' analysis, Immunovia AB (OSTO:IMMNOV) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.07, compared to a current price of kr0.19 — trading 171.4% above its estimated fair value. The current Median PS Value is kr11.65, which is 116400% above median its 10-year median of 0.01. Immunovia AB's overall GF Score™ is 43/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Immunovia AB (OSTO:IMMNOV), the current Median PS Value is kr11.65 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunovia AB (OSTO:IMMNOV) Overvalued in 2026?
Based on GuruFocus' analysis, Immunovia AB stock appears to be overvalued.
The current stock price of kr0.19 is trading 171.4% above its estimated GF Value™ of kr0.07.
GuruFocus considers Immunovia AB to be Significantly Overvalued.
Key valuation signals for OSTO:IMMNOV:
Median PS Value: kr11.65 (116400% above median its 10-year median of 0.01)
GF Value™: kr0.07 vs. price of kr0.19 (171.4% above fair value)
No single metric tells the full story. See the OSTO:IMMNOV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunovia AB is a diagnostic company. The company develops and commercializes diagnostic tools to detect proteins and autoimmune diseases. The company is developing its next-generation blood test to detect pancreatic cancer in high-risk individuals. IMMray platform is dedicated to the early detection of pancreatic cancer. Its technology platform IMMray (TM), is based on antibody microarray analysis.
43GF Score
Get the complete analysis for OSTO:IMMNOV
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IMMNOV has been successfully added to your 
